| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
127,464 |
121,676 |
$10.90M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
10,978 |
9,611 |
$2.35M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
59,768 |
53,887 |
$2.28M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
36,415 |
33,915 |
$1.75M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
20,046 |
18,370 |
$578K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
8,737 |
8,250 |
$553K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
3,278 |
3,075 |
$414K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,105 |
6,516 |
$390K |
| 87428 |
|
9,001 |
8,039 |
$270K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
6,959 |
6,394 |
$209K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
9,717 |
9,239 |
$199K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,703 |
2,398 |
$185K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,249 |
2,993 |
$150K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
5,386 |
4,826 |
$118K |
| 87529 |
|
2,541 |
2,260 |
$111K |
| 87640 |
|
7,234 |
6,356 |
$105K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
8,657 |
7,888 |
$92K |
| 87481 |
|
2,593 |
2,305 |
$88K |
| 87641 |
|
5,178 |
4,677 |
$82K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,691 |
4,313 |
$78K |
| 87634 |
|
2,839 |
2,650 |
$71K |
| 87653 |
|
2,832 |
2,549 |
$61K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,536 |
2,263 |
$56K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,530 |
2,258 |
$55K |
| 87581 |
|
3,586 |
3,298 |
$54K |
| 87541 |
|
3,537 |
3,246 |
$52K |
| 87486 |
|
3,535 |
3,248 |
$52K |
| 87498 |
|
3,219 |
2,944 |
$46K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
2,473 |
2,206 |
$45K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,813 |
3,140 |
$39K |
| 99051 |
|
4,782 |
4,544 |
$29K |
| 87511 |
|
1,837 |
1,627 |
$29K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,645 |
1,408 |
$22K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
602 |
500 |
$22K |
| D0150 |
Comprehensive oral evaluation - new or established patient |
479 |
423 |
$17K |
| D1120 |
Prophylaxis - child |
617 |
557 |
$17K |
| 86769 |
|
414 |
211 |
$16K |
| 86328 |
|
743 |
639 |
$14K |
| 87500 |
|
561 |
534 |
$13K |
| 87632 |
|
149 |
146 |
$11K |
| 87563 |
|
258 |
248 |
$9K |
| 81025 |
|
1,433 |
1,340 |
$8K |
| D1351 |
Sealant - per tooth |
233 |
56 |
$8K |
| D1206 |
Topical application of fluoride varnish |
471 |
425 |
$8K |
| 81002 |
|
3,542 |
3,228 |
$8K |
| D2391 |
Resin-based composite - one surface, posterior, primary or permanent |
75 |
48 |
$7K |
| 99385 |
|
115 |
110 |
$7K |
| D1208 |
Topical application of fluoride, excluding varnish |
247 |
226 |
$7K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
426 |
403 |
$7K |
| 80305 |
|
822 |
740 |
$6K |
| D0272 |
Bitewings - two radiographic images |
479 |
429 |
$6K |
| 36415 |
Collection of venous blood by venipuncture |
2,156 |
1,956 |
$5K |
| D0120 |
Periodic oral evaluation - established patient |
233 |
222 |
$5K |
| 99442 |
|
119 |
97 |
$5K |
| D0330 |
Panoramic radiographic image |
56 |
51 |
$4K |
| 81513 |
|
73 |
72 |
$4K |
| D1110 |
Prophylaxis - adult |
74 |
68 |
$4K |
| 99386 |
|
46 |
44 |
$4K |
| 71046 |
Radiologic examination, chest; 2 views |
187 |
187 |
$4K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
129 |
118 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
15 |
13 |
$2K |
| D0274 |
Bitewings - four radiographic images |
74 |
68 |
$2K |
| 81514 |
|
37 |
35 |
$2K |
| 73630 |
|
102 |
99 |
$2K |
| 99205 |
Prolong outpt/office vis |
19 |
15 |
$2K |
| 84449 |
|
125 |
116 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
150 |
135 |
$1K |
| 93000 |
|
78 |
78 |
$1K |
| 73610 |
|
62 |
59 |
$964.31 |
| 73130 |
|
53 |
52 |
$962.43 |
| 80053 |
Comprehensive metabolic panel |
160 |
145 |
$948.96 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
13 |
13 |
$915.72 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
14 |
14 |
$817.20 |
| 76830 |
Ultrasound, transvaginal |
14 |
14 |
$817.20 |
| 80061 |
Lipid panel |
112 |
102 |
$785.84 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
12 |
12 |
$777.84 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
174 |
157 |
$742.28 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
179 |
164 |
$686.14 |
| 0012A |
|
28 |
28 |
$634.55 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,208 |
1,072 |
$528.48 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
38 |
19 |
$517.50 |
| 0011A |
|
36 |
36 |
$462.46 |
| 83037 |
|
87 |
77 |
$454.25 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
85 |
81 |
$448.28 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
418 |
347 |
$441.23 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
95 |
53 |
$425.76 |
| 80306 |
|
77 |
61 |
$417.57 |
| 97597 |
|
17 |
13 |
$312.46 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
29 |
28 |
$296.92 |
| D0230 |
Intraoral - periapical each additional radiographic image |
60 |
16 |
$260.00 |
| 99406 |
|
26 |
26 |
$180.00 |
| D0220 |
Intraoral - periapical first radiographic image |
33 |
30 |
$160.00 |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
2,492 |
2,313 |
$140.00 |
| 69209 |
|
16 |
16 |
$111.53 |
| 86308 |
|
30 |
30 |
$100.95 |
| 36416 |
|
36 |
36 |
$83.49 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
79 |
77 |
$49.45 |
| 82270 |
|
12 |
12 |
$32.90 |
| 99173 |
|
14 |
14 |
$7.20 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
86 |
82 |
$5.33 |
| 1159F |
|
648 |
581 |
$0.00 |
| 99072 |
|
1,593 |
1,463 |
$0.00 |
| 90715 |
|
13 |
13 |
$0.00 |
| 90734 |
|
13 |
13 |
$0.00 |
| 1036F |
|
451 |
391 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
17 |
16 |
$0.00 |
| T1503 |
Administration of medication, other than oral and/or injectable, by a health care agency/professional, per visit |
28 |
28 |
$0.00 |